Form 4: Rhythm Pharma CTO Granted Equity Awards

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, was granted 15,000 restricted stock units and 22,500 stock options.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), was granted equity awards on February 11, 2026.
• The awards include 15,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The RSUs vest in four equal annual installments of 25% on February 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.
• Additionally, 22,500 stock options were granted with an exercise price of $98.47 per share and an expiration date of February 10, 2036.
• These stock options vest in 16 substantially equal installments upon completion of each three full months of successive service to the Issuer following the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices designed to align management incentives with long-term shareholder value, without indicating any immediate operational or financial changes.

Positives

• The grant of equity awards to the Chief Technical Officer aligns his interests with long-term shareholder value creation.
• The vesting schedules for both RSUs and stock options incentivize continued service and performance from a key executive.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports routine compensation.

Future Outlook

The equity awards, with their multi-year vesting schedules extending to 2030 for RSUs and 2036 for stock options, indicate a long-term commitment to the company's future performance and executive retention.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Technical Officer are standard practice in the biotechnology and pharmaceutical industry. These grants are crucial for attracting and retaining top talent, especially in a sector reliant on innovation and long-term development cycles. The vesting schedules are typical for incentivizing sustained performance and alignment with shareholder interests over several years.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of Restricted Stock Units (RSUs) and stock options with multi-year vesting, is consistent with executive compensation practices observed at comparable biotech firms such as Vertex Pharmaceuticals (VRTX) or Regeneron Pharmaceuticals (REGN), which often use similar long-term incentive plans to retain key scientific and technical leadership.
• The exercise price of $98.47 for the stock options reflects the market price at the time of grant, a common practice to ensure options provide value only if the stock price appreciates, aligning executive incentives with stock performance.

Stakeholder Impact

• Shareholders: Potential positive impact as executive incentives are aligned with long-term stock performance.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• Joseph Shulman's continued service to the Issuer to fulfill vesting requirements for both RSUs and stock options.
• Future reporting of any sales or further acquisitions of Rhythm Pharmaceuticals securities by Joseph Shulman via subsequent Form 4 filings.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a key executive, Joseph Shulman, as part of his compensation. While it aligns management incentives with long-term shareholder value, it does not present new information that would fundamentally alter the investment thesis for Rhythm Pharmaceuticals. It's a standard operational event, thus a 'hold' recommendation is appropriate as it doesn't provide a strong catalyst for either buying or selling based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, Joseph Shulman, Chief Technical Officer, Restricted Stock Units, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Form 4